Frontline Serplulimab Extends Survival in SCLC

by | Jun 10, 2026 | Health

Spread the love
Four-year follow-up from the ASTRUM-005 trial shows durable survival benefits with first-line serplulimab plus chemotherapy in extensive-stage SCLC.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments